This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Company Overview - Neurocrine Biosciences, Inc. (NASDAQ: NBIX) is a San Diego-based drug developer that completed its initial public offering (IPO) in 1996, raising $36.75 million [2]. Investment Insights - The investment group Haggerston BioHealth provides insights for both novice and experienced biotech investors, including catalysts to watch for, buy and sell ratings, product sales forecasts, and integrated financial statements [2]. Analyst Background - The article is authored by a biotech consultant with over 5 years of experience covering biotech, healthcare, and pharma, having prepared detailed reports on over 1,000 companies [2].

Core Insights - Neurocrine Biosciences presented new data indicating that all patients with tardive dyskinesia achieved a therapeutic dose with INGREZZA (valbenazine) from the start of treatment, contrasting with only about half of patients on deutetrabenazine reaching a therapeutic dose within six months [1][5][6] Group 1: Study Findings - The retrospective cohort study included 3,527 patients treated with INGREZZA, 2,166 with deutetrabenazine BID, and 326 with deutetrabenazine XR, assessing them over a six-month period [2][3] - Results showed that 100% of patients on INGREZZA reached a therapeutic dose immediately, while only 47.5% of those on deutetrabenazine BID and 54.3% on XR achieved this within six months [6] - The average time to reach a therapeutic dose for deutetrabenazine patients was three to four weeks, with nearly 10% unable to maintain the therapeutic dose after reaching it [6] Group 2: Treatment Implications - INGREZZA's ability to provide a therapeutic dose from day one without titration may reduce the burden on clinicians and patients associated with sub-therapeutic dosing [2][5] - Fewer patients on INGREZZA experienced dose changes compared to those on deutetrabenazine, with 33.7% of INGREZZA patients needing a dose change after the first month, compared to 48.1% for BID and 54.0% for XR [6] Group 3: About Tardive Dyskinesia - Tardive dyskinesia is a movement disorder characterized by uncontrollable and repetitive movements, often resulting from the use of certain antipsychotic medications [4][7] - It is estimated to affect at least 800,000 adults in the U.S., highlighting the significant need for effective treatments [7] Group 4: About INGREZZA - INGREZZA is a selective VMAT2 inhibitor approved for treating tardive dyskinesia and chorea associated with Huntington's disease, uniquely offering a therapeutic dose from day one [8][9] - The medication is available in 40 mg, 60 mg, and 80 mg capsules, and can be taken alongside most stable mental health regimens [10][19]

Our Purpose: To make the world smarter, happier, and richer. Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, top-rated podcasts, and non-profit The Motley Fool Foundation. ...

Core Insights - Neurocrine Biosciences presented new data from the KINECT® 4 study showing that the majority of patients treated with INGREZZA® (valbenazine) capsules achieved remission of tardive dyskinesia (TD) [1][7] Study Findings - The KINECT 4 study involved 163 participants with moderate to severe TD and underlying psychiatric conditions, who received 48 weeks of treatment with INGREZZA [4] - A post-hoc analysis indicated that 59.2% of participants achieved remission, with 58.6% on the 40 mg dose and 59.5% on the 80 mg dose [8] - Significant improvements in the Abnormal Involuntary Movement Scale (AIMS) total scores were observed, with mean baseline scores decreasing from 12.4 (40 mg) and 15.1 (80 mg) to 2.1 and 2.5, respectively, at Week 48 [8] Treatment Efficacy - The findings suggest that INGREZZA is an effective long-term treatment option for TD, regardless of the underlying psychiatric condition [2][3] - Improvements in TD symptoms were consistent across different psychiatric diagnoses, with remission rates of 57.7% for schizophrenia or schizoaffective disorder and 62.5% for mood disorders [8] Safety and Tolerability - INGREZZA was generally well tolerated, with treatment emergent adverse events occurring in ≥ 5% of participants being urinary tract infection (8.5%) and headache (5.2%) [5] - Changes in psychiatric stability and vital signs were generally small and not clinically significant [5] About INGREZZA - INGREZZA is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved for treating adults with tardive dyskinesia and chorea associated with Huntington's disease [10][11] - The drug is unique in that it offers a therapeutic dose from day one without the need for titration [10]

Data Reinforce the Clinically Meaningful Impact of INGREZZA in Adults with Huntington's Disease Chorea Findings Presented at the 2025 American Association of Neuroscience Nurses Neuroscience Advanced Practice Provider SymposiumSAN DIEGO, March 17, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) presented data from the KINECT®-HD study showcasing significant improvements in chorea across body regions with once-daily INGREZZA® (valbenazine) capsules in adults with Huntington's disease. The p ...

Core Insights - Neurocrine Biosciences has initiated a Phase 1 clinical study for NBI-1140675, an investigational oral selective second-generation small molecule inhibitor of VMAT2, aimed at treating neurological and neuropsychiatric conditions [1][2] - The company aims to expand its portfolio of VMAT2 inhibitors, building on the success of valbenazine, which is approved for tardive dyskinesia and chorea associated with Huntington's disease [2] Company Overview - Neurocrine Biosciences is a leading biopharmaceutical company focused on neuroscience, dedicated to developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders [3] - The company has a diverse portfolio that includes FDA-approved treatments for various conditions and a robust pipeline with multiple compounds in mid- to late-phase clinical development [3]

SAN DIEGO, Feb. 27, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced top-line data from a Phase 4 study, KINECT-PRO™, demonstrating clinically meaningful and sustained effects of INGREZZA® (valbenazine) capsules on the physical, social and emotional impacts experienced by patients living with tardive dyskinesia (TD), irrespective of TD severity or underlying psychiatric condition. KINECT-PRO is the first study to show patient-reported impact of a vesicular monoamine transport ...

SAN DIEGO, Feb. 25, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in March. Chief Executive Officer Kyle Gano, Chief Financial Officer Matt Abernethy, and Chief Commercial Officer Eric Benevich will present at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025 at 11:10 AM Eastern Time in Boston. Chief Financial Officer Matt Abernethy and Vice-President of Investor Relations Todd Tushla will present at the Leerin ...

SAN DIEGO, Feb. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which Neurocrine Biosciences may repurchase up to $500 million of its shares, subject to market conditions. This new share repurchase authorization is in addition to the $300 million accelerated repurchase program that was announced in October 2024 and completed in early February 2025.William Rastetter, Chairman of the Board of D ...